CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, discusses the global relevance of the Company’s DNA Repair program, as well as the significance of the recently released first results from the CUV151 study in healthy volunteers.
Stay up to date on our DNA Repair Program: https://www.clinuvel.com/disease-entities/dna-repair/
Read the technical note accompanying the CUV156 announcement: https://www.clinuvel.com/afamelanotide-significantly-reduces-uv-skin-damage-in-a-healthy-population-technical-note-20230202/
In case you missed it, watch CLINUVEL’s Genomic Expert Dr Jessica Nucci discuss the science behind the CUV156 results: https://youtu.be/Hz1SyWyJnyI